Luigi Antelmi

biomedical engineer luigi.antelmi@hcuge.ch

Brain images data mining: what's next?

CERN openlab "IT in Healthcare" Workshop Geneva, Tuesday, 11 November 2014

Numbers and facts about Dementia

- ~35M people have dementia today. ~70M by 2030 and ~115M by 2070.
- When a diagnosis is made, it often comes at a relatively late stage of the disease.
- Alzheimer's disease is the most common cause of dementia (up to 70% of cases).
- Current drugs can in the best hypothesis just slow down the progression of the disease. Healthy Severe AD
- Currently there is no cure.

Twin Labs

Brescia, Italy



IRCCS CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI – BRESCIA

Centro Nazionale per lo Studio e la Cura della Malattia di Alzheimer e Malattie Mentali




Geneva, Switzerland




Laboratory of Neuroimaging of Aging





High Performance Computing



neuGRID: a grid-based image analysis environment

_arge

image

datasets

Read More »

Read More »

ADDNEUROMED


AddNeuro

Stu

LADIS


ADNI

Read More »



neuGRID

Graphical Interface Single case analysis Physician oriented



Command Line Interface

Parallel processing Research Oriented

```
andora_user2@ng-hug-server4:~$
                    \_bias1X.xfm
                   D\ bias1X.xfm
                           rmcode 1 ${ID}_nuC.nii.gz
|}_nuC.nii.gz -ref ${ID}_nuC.nii.gz -applyxfm -init $ID\_bias
           S{ID} std.nii.az
      TH\fslmaths $ID\_std.nii.gz -inm 28.32 ${ID}_norm.nii.gz # 28.32 = icbm152 mean
   [ID]_std.nii.gz
  _PATH\fslmaths ${ID}_norm.nii.gz -kernel sphere 2 -fmedian ${ID}_norm_median-Sph2.n
 L_PATH\bet ${ID}_norm_median-Sph2.nii.gz ${ID}_norm_median-Sph2_bet.nii.gz -B
   PATH\flirt -in ${ID}_norm_median-Sph2_bet.nii.gz -ref $TEMPLATE_BRAIN -omat ${ID
```

Report for Clinicians

ACM-AdaBoost Report




Subject info

Patient ID: TestImageDICOMS Sex: M Age: 60

ACM-AdaBoost¹ Results

Model: wl3-75k-v2.0

Left Volume: $3822 \text{ } mm^3$ Right Volume: $3194 \text{ } mm^3$



Every colored line represents the Prediction Percentile for the hippocampus volume of a non-pathological subject.




Figure 1: Segmentation of the brain scan registered to the ICBM-152 template. The letter "R" identifies the Right direction. (a) Axial view. (b) Coronal view. (c) Sagittal view centered on the Right Hippocampus. (d) Sagittal view centered on the Left Hippocampus.

¹ J. H. Morra, Z. Tu, L.G. Apostolova, A.E. Green, C. Avedissian, S.K. Madsen, N. Parikshak, X. Hua, A.W. Toga, C.R. Jack, M.W. Weiner, P.M. Thompson. Validation of a fully automated 3D hippocampal segmentation method using subjects with Altheimer's disease mild cognitive impairment, and elderly controls. Neuroimage, 43 (2008), 1:59-68.

Scientific achievements





The hippocampal boundary shift integral is 70% more reproducible than FreeSurfer, manual and other hippocampal atrophy measurement algorithms

Keith S Cover^a, Ronald A van Schijndel^a, Adriaan Versteeg^a, Kelvin K Leung^b, Emma R Mulder^a, Remko A de Jong^a, Pieter J Visser^a, Baptiste Grenier^c, Jérôme Revillard^c, David Manset^c, Alberto Redolfi^d, Bob W van Dijk^a, Hugo Vrenken^a, Nick C Fox^b, Frederik Barkhof^a

aVU University Medical Center, Amsterdam bUCL, London cgnubila, France dIRCCS San Giovanni di Dio Fatebenefratelli, Brescia, Italy (Contact: Keith@kscover.c















Conclusions

- MAPS-HBSI is roughly 70% more reproducible, based on BTB, than FreeSurfer, manual and the other algorithms
- ADNI1 post processing does not introduce significant noise based on the left-right symmetry of annualised PVC scatter plots
- The improved atrophy measurement is a step closer to hippocampus atrophy as a biomarker for individuals in AD



2011: New Criteria for AD diagnosis



Alzheimer's

Output

Dementia

Alzheimer's & Dementia 7 (2011) 280-292

Toward defining the preclinical stages of Alzheimer's disease:

Recommendations from the National Institute on Aging-Alzheimer's

Association workgroups on diagnostic guidelines

for Alzheimer's disease


- Preclinical AD: a new concept that indicates that changes in the brain, can be detected before there are any clinical symptoms
- changes in the brain can begin 10 or more years before clinical symptoms like memory loss appear.
- Research must focus on finding early disease biomarkers.


What we are currently able to measure: the biomarkers

- Geometry (MRI)
- Functionality (fdg-PET, fMRI)
- Amyloid load (CSF, amy-PET)
- Pattern of atrophy/functionality











Hypothetical model of dynamic biomarkers



Tough Problems


Navier-Stokes

$$\rho \left(\frac{\partial v}{\partial t} + v \cdot \nabla v \right) = -\nabla p + \nabla T + f$$




Black-Scholes

$$\frac{\partial V}{\partial t} + \frac{1}{2}\sigma^2 S^2 \frac{\partial^2 V}{\partial S^2} + rS \frac{\partial V}{\partial S} = rV$$






$$\frac{\partial ?}{\partial t} = f(?,!,\omega)$$



Advantages of a quantitative model

- Quantify disease dynamics
 - Disease tracking (pharma)
 - Early diagnosis (clinicians)
- Identify drugs that works
 - Short-term end-points
- Personalized medicine
- Test hypothesis on disease origins
 - Tau vs Beta debate



$$\frac{\partial ?}{\partial t} = f(?,!,\varpi)$$